ADAMTS13 and thrombotic thrombocytopenic purpura: Patients with genetic HUS that result from congenital deficiencies of complement pathway regulators, or congenital TTP that result from a congenital deficiency of ADAMTS13, may benefit from the replacement of these factors through plasma infusions.